Apyx Medical (APYX) Cash & Equivalents (2010 - 2026)

Apyx Medical (APYX) has reported Cash & Equivalents for 17 consecutive years, with $27.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 5.75% year-over-year to $27.6 million; the trailing twelve-month figure through Jun 2026 stood at $27.6 million (down 5.75% YoY), and the FY2025 full-year result was $31.7 million, changed 0.0% from the prior year.
• Cash & Equivalents slipped to $27.6 million in Q2 2026 per APYX's latest filing, from $31.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $43.7 million in Q4 2023 and bottomed at $10.2 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $26.5 million across 5 years, with a median of $27.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents sank 66.98% in 2022, then jumped 328.3% in 2023.
• Over 5 years, Cash & Equivalents stood at $10.2 million in 2022, then surged by 328.3% to $43.7 million in 2023, then dropped by 27.29% to $31.7 million in 2024, then dropped by 0.0% to $31.7 million in 2025, then fell by 12.99% to $27.6 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $27.6 million, $31.1 million, and $31.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.